Back to MPT Database

Tenofovir + Levonorgestrel IVR

Polyurethane, dual-reservoir ring designed for 3 months of continuous use, or with up to 3 days intermittent removal. The first-in-women Phase I trial (CONRAD-128) completed in 2016 and successfully met all performance benchmarks. An expanded Phase I study (CONRAD-138) was completed in early 2019; results expected mid-2020. A first-in-kind study to evaluate MPT IVRs in Africa, the CDC Kisumu Combined Ring Study (CONRAD B17-144) was completed in late 2019; results expected in late 2020.

Development Stage:

Clinical – Phase 2 Trial (C2)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Topical - Intravaginal Ring (IVR)

Mechanism of Action:

nucleoside analogue reverse transcriptase inhibitor (NRTI), progestin

Developer:

  • CONRAD

Funding:

  • Centers for Disease Control and Prevention (CDC)
  • U.S. Agency for International Development (USAID)

Funding Mechanism:

USAID: Cooperative Agreement

Past Funding:

Bill & Melinda Gates Foundation
NIH: Interagency Agreements to USAID

Back to MPT Database